Patients with low-volume metastatic disease and TP53 mutation exhibited clinical outcomes like those with high-volume metastatic disease, suggesting that genomic characteristics of the tumor may be more relevant for prognosis than disease burden [38]. Here, TP53 is linked to metastatic neoplasm.